Abstract
Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is also some evidence for increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia and 355 healthy age-matched men were included. Urinary non-isomerized (α CTX) and β isomerized (β CTX) type I collagen C-telopeptides (CTX) and a new assay for serum CTX were used to assess bone resorption. Bone formation was determined by serum osteocalcin, serum total (T-ALP) and bone (BAP) alkaline phosphatase and serum type I collagen C-terminal propeptide (PICP). Fourteen patients with bone metastases were also evaluated 15 days after a single injection of the bisphosphonate pamidronate (120 mg). Levels of all bone formation and bone resorption markers were significantly (P< 0.006–0.0001) higher in patients with prostate cancer and bone metastasis than in patients with benign prostatic hyperplasia, patients with prostate cancer without bone metastases and healthy controls. In patients with bone metastases the median was increased by 67% for serum osteocalcin, 128% for T-ALP, 138% for BAP, 79% for PICP, 220% for urinary α CTX, 149% for urinary β CTX and 214% for serum CTX. After bisphosphonate treatment all three resorption markers significantly decreased by an average of 65% (P = 0.001), 71% (P = 0.0010) and 61% (P = 0.0015) for urinary α CTX, urinary β CTX and serum CTX, respectively, whereas no significant change was observed for any bone formation markers. Patients with prostate cancer and bone metastases exhibit a marked increase in bone resorption, which decreases within a few days of treatment with pamidronate. These findings suggest that these new resorption markers may be useful for the management of these patients. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adami S (1997) Bisphosphonate in prostate cancer. Cancer 80: 1674–1679
Adami S, Salvagno G, Guarrera Bianchi G, Dorizzi R and Rosini S (1985) Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 134: 1152–1154
Akimoto S, Furuya Y, Akakura K and Ito H (1998) Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastases. Endocrine J 45: 97–104
Berenson JR, Lichtensein A, Poter L, Di MoPoulos MA, Bordini C, George S, Lipton A, Keller A, Ballester O, Koracs MJV, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan PD, Seaman J and Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced myeloma. N Engl J Med 334: 488–493
Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccoti P, Doglotti L and Angeli A (1996) Biochemical evaluation of bone turnover in cancer patients: relationship with radiograph appearances and disease extension. Br J Cancer 73: 1581–1587
Blom E, Ali MM, Mortensen B and Huseby NE (1998) Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta 270: 125–137
Body J-J, Coleman RE and Piccart M (1996) Use of bisphosphonates in cancer patients. Cancer Treat Rev 22: 265–287
Bonde M, Qvist P, Fledelius C, Riis BJ and Christiansen C (1994) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40: 2022–2025
Bonde M, Fledelius C, Qvist P and Christiansen C (1996) A coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem 42: 1639–1644
Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD and Christiansen C (1997) Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an eight amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 12: 1028–1034
Carey PO and Lippert MC (1988) The treatment of painful prostatic bone metastases with oral etidronate sodium. Urology 32: 403–407
Christgau S, Alexendersen P, Schlemmer A, Bonde M and Christiansen C (1997) Biological variation of the serum concentration of degradation products derived from the C-terminal telopeptide of type I collagen measured by a new version of the Crosslaps ELISA. J Bone Miner Res 12: S497
Clarke NW, McClure J and George NJR (1991) Morphometric evidence for bone resorption and replacement in prostate cancer. Brit J Urol 68: 74–80
Clarke NW, McClure J and George NJR (1992) Dissodium pamidronate identifies differential bone resorption in metastatic prostate cancer. Br J Urol 69: 64–70
Coleman RE (1998) Monitoring of bone metastases. Eur J Cancer 34: 252–259
Coleman RE, Purohit OP and Vinholes J (1996) Improved quality of life with high dose bisphosphonate treatment: The UK experience. In: Bisphosphonates – Improved Treatment of Osteolysis in Malignant and Non-malignant Indications, Possinger K, Ziegler R (eds), pp. 37–48, Excerpta Oncologica Ciba Wehr/Baden: Ciba Geigy Verlag
Delmas PD, Demiaux B, Malaval L, Chapuy MC and Meunier PJ (1986) Serum bone-GLA-protein is not a sensitive marker of bone turnover in Paget’s disease of bone. Calcif Tissue Int 38: 60–61
Elomaa I, Kylmala T and Tammela T (1992) Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 24: 159–166
Engler H, Koeberle D, Thuerlimann B, Senn HJ and Riesen WF (1998) Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med 36: 879–885
Fledelius C, Johnsen AH, Cloos PAC, Bonde M and Qvist P (1997) Characterization of urinary degradation products derived from Type I collagen. J Biol Chem 272: 9755–9763
Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P and Delmas PD (1992) Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 7: 1389–1398
Garnero P, Shih WJ, Gineyts E, Karpf D and Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate. J Clin Endocrinol Metab 79: 1693–1700
Garnero P, Fledelius C, Gineyts E, Serre C-M, Vignot E and Delmas PD (1997) Decreased β isomerisation of C-telopeptides of type I collagen in Paget’s disease of bone. J Bone Miner Res 12: 1407–1415
Garnero P, Gineyts E, Shaffer AV, Seaman S and Delmas PD (1998) Measurement of urinary excretion of nonisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum 41: 354–360
Gomez B, Ardakani S, Ju J, Jenkins D, Cerelli M-J, Daniloff GY and Kung VT (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase in serum. Clin Chem 41: 1560–1566
Hannon R, Blumsohn A, Naylor K and Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13: 1124–1133
Hassager C, Jensen LT, Podenphant J, Thomsen K and Christiansen C (1994) The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of Nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 54: 30–33
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheller H, Simeone JF, Seaman J, Knight RD, Heffernan M and Reitsman DJ (1996) Efficacy of pamidronate in reducing skeletal events in patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1785–1791
Ikeda I, Miura T and Kondo I (1996) Pyridinium crosslinks as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 77: 102–106
Koizumi M, Maeda H, Yoshimura K, Yamauchi T, Kawai T and Ogata E (1997) Dissociation of bone metabolic markers in bone metastasis of prostate cancer. Br J Cancer 75: 1601–1604
Kylmala T, Tammela T, Risteli L, Risteli J, Taube T and Elomaa I (1993) Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 29A: 821–825
Kylmala T, Risteli J and Elomaa I (1995) Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71: 1061–1064
Lorente JA, Morote J, Raventos C, Encabo G and Valenzuela H (1996) Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 155: 1348–1351
Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T and Ogata E (1997) Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 157: 539–543
Myamoto KK, McSkerry SA, Robins SA, Besterman J and Mohler JL (1994) Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 151: 909–913
Nakashima J, Sumitomo M, Miyajima A, Jitsukawa S, Saito S, Tachibana M and Murai M (1997) The value of serum carboxyterminal propeptide of type I procollagen in predicting bone metastases in prostate cancer. J Urol 157: 1736–1739
Nguyen-Pamart M, Caty A, Feutrie ML, Fournier C, Gosselin P and Mazeman E (1997) The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer. Br J Urol 80: 452–455
Pecherstorfer M, Zimmer-Roth J, Shilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H and Seibel MJ (1995) The diagnostic value of urinary pyridinium crosslinks of collagen, alkaline phosphatase and urinary calcium in neoplastic bone disease. J Clin Endocrinol Metab 80: 97–103
Pelger RCM, Hamdy NAT, Zwinderman AH, Lycklama AAB, Nijeholt A and Papapoulos SE (1998) Effects of bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22: 403–408
Pollen JJ, Witztun KF and Ashburn WL (1984) The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Radiother 142: 773–776
Price PA, Williamson MK and Lothinger JW (1981) Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 256: 12760–12766
Risteli J, Elomaa I, Niemi S, Novamo A and Risteli L (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39: 635–640
Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P and Christiansen C (1998) Serum crosslaps one-step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44: 2281–2289
Sano M, Kushida K, Takahashi M, Ohishi T, Kawana M, Okada M and Inoue T (1994) Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastases. Br J Cancer 70: 701–703
Smedsrod B, Melkko J, Risteli L and Risteli J (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271: 345–350
Soloway MS, Hardeman SW, Hickey D, Raymond JT, Todd B and Soloway S (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195–202
Takeuchi S-I, Arai K, Saitoh H, Yoshida K-I and Miura M (1996) Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastases in patients with prostate cancer. J Urol 156: 1691–1695
Taube T, Kylmälä TC, Lamberq-Allard C, Tammela TLJ and Elomaa I (1994) The effect of clodronate in metastatic prostate cancer: histomorphometric report of a double-blind randomised placebo controlled study. Eur J Cancer 30: 751–758
Uebelhart D, Gineyts E, Chapuy MC and Delmas PD (1990) Urinary excretion of pyridinium cross links: a new marker of bone resorption in metabolic bone disease. Bone Miner 8: 87–96
Urwin GH, Percival RC, Harris S, Beneton MNC, Williams JL and Kanis SA (1985) Generalised increase in bone resorption in carcinoma of prostate. Eur J Urol 57: 721–723
Vinholes JJ, Guo C-Y, Purohit OP, Eastell R and Coleman RE (1996) Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 73: 1089–1095
Vinholes JJ, Purohit OP, Abbey ME, Eastell R and Coleman RE (1997) Relationships between biochemical and symptomatic response in a double-blind trail of pamidronate for metastatic disease. Ann Oncol 8: 1243–1250
Winterbottom N, Vernon S, Freeman K, Daniloff G and Seyedin S (1993) A serum immunoassay for the C-terminal propeptide of type I collagen. J Bone Miner Res 8: S341
Young GP, Rose IS, Cropper S, Seetharam S and Alpers DH (1984) Hepatic clearance of rat intestinal alkaline phosphatase. Am J Physiol 274: G419–426
Yoshida K-I, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H and Kitahara S (1997) Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate cancer. Cancer 80: 1760–1767
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Garnero, P., Buchs, N., Zekri, J. et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82, 858–864 (2000). https://doi.org/10.1054/bjoc.1999.1012
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1012
Keywords
This article is cited by
-
Bone marrow lesion severity was associated with proximal tibial inclination in early knee osteoarthritis
Knee Surgery, Sports Traumatology, Arthroscopy (2022)
-
Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review
Journal of Orthopaedic Surgery and Research (2021)
-
Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review
Journal of Orthopaedic Surgery and Research (2021)
-
Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases
EJNMMI Research (2017)
-
Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy
Endocrine (2015)